Position in RGNX
as of Mar 31, 2026
· filed May 8, 2026
Position Value
$799,452
+$799,452 QoQ
Shares Held
95,400
Ownership
0.145%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2023
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in RGNX Over Time
Shares Held
Position Value (USD)
Derivatives in RGNX
reported options exposure · as of Sep 30, 2024CallValue
$0
CallShares
0
PutValue
$4,196,000
PutShares
400,000
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Jefferies Financial Group Inc. holds $677,219,224 across 66 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PTCT |
Ptc Therapeutics, Inc.
|
1,357,042 | $110,693,915 | |
| 2 | URGN |
UroGen Pharma Ltd.
|
2,199,652 | $80,947,193 | |
| 3 | IMTX |
Immatics N.V.
|
6,506,802 | $65,913,904 | |
| 4 | TNGX |
Tango Therapeutics, Inc.
|
2,010,534 | $62,849,292 | |
| 5 | CGON |
CG Oncology, Inc.
|
769,947 | $54,704,734 | |
| 6 | ARGX |
Argenx SE
|
45,068 | $41,812,738 | |
| 7 | RARE |
Ultragenyx Pharmaceutical Inc.
|
929,626 | $31,040,212 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
466,258 | $26,679,282 |
All Filings in RGNX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $799,452 | 95,400 | Shares | Defined | 2026-05-08 | |
| 2024-09-30 | $4,196,000 | 400,000 | Put | Defined | 2024-11-14 | |
| 2023-03-31 | $1,272,851 | 67,311 | Shares | Defined | 2023-05-15 | |
| No filing history on record for this holder in this stock. | ||||||